IMBG is being studied in Rheumatoid Arthritis under a comprehensive clinical plan program, which includes an already running first proof of concept clinical study in 100 patients (BH-Pilot Study 2018 in Rheumatoid Arthritis) and a it is planned to be followed by a subsequent validation study

BH-Pilot Study 2018 in Rheumatoid Arthritis aims to evaluate the feasibility and potential clinical utility of a specifically-developed IMBG for Rheumatoid Arthritis. This first-in-clinic study is being done in collaboration with the Rheumatology Unit of “Reina Sofía” Hospital (Córdoba) and “Maimonides Institute of Biomedical Research” (IMBIC).

It will include 100 Rheumatoid Arthritis patients classified in the following categories:

  1. Naïve patients
  2. Chronic patients under treatment with DMARDs with low disease activity
  3. Chronic patients under treatment with DMARDs with high disease activity

We expect BH- Pilot Study 2018 in Rheumatoid Arthritis to be a clinical study that will demonstrate:

1) IMBG -RA will be feasible in patients with Rheumatoid Arthritis at various disease stages and clinical scenarios

2) IMBG-RA will offer an in vitro potency evaluation of Immunosuppressant drugs (IS) that will correlate with sensitivity grades of the patient to a panel of IMs

3) A significant proportion of patients with non-controlled RA will show low-sensitivity patterns in IMBG -RA to the medication they are taking